WELLBUTRIN

Compare WELLBUTRIN  to:
Compare
Compare

Generic Name for WELLBUTRIN

Bupropion HCl 75mg, 100mg; immediate-rel tabs.

Legal Classification:

Rx

Pharmacological Class for WELLBUTRIN

Aminoketone.

Manufacturer of WELLBUTRIN

GlaxoSmithKline Pharmaceuticals

Indications for WELLBUTRIN

Depression.

Adult dose for WELLBUTRIN

Avoid bedtime dosing. ≥18yrs: initially 100mg twice daily for at least 3 days; if tolerated, increase to 100mg 3 times daily at least 6 hrs apart; max increase 100mg/day per 3-day period. May increase after several weeks to max 450mg/day in 3 divided doses; max single dose: 150mg (give 400mg/day as 100mg 4 times daily at least 4 hrs apart). Severe hepatic cirrhosis: max 75mg once daily. Mild-moderate hepatic cirrhosis, or renal impairment: consider reduced dose and/or dose frequency.

Children's dosing for WELLBUTRIN

<18yrs: not recommended.

Also:

Contraindications for WELLBUTRIN

Seizure disorders. Bulimia. Anorexia nervosa. Within 14 days of MAOIs. Abrupt withdrawal of sedatives or alcohol. Other forms of bupropion (eg, Zyban).

Warnings/Precautions for WELLBUTRIN

History or risk of seizures; discontinue if seizure occurs: do not restart. Hepatic or renal impairment (monitor closely). Depression: clinical worsening or suicidal risk (monitor). Bipolar disorder. Psychosis. Unstable heart disease. CHF. Recent MI. Maintain at lowest effective dose. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for WELLBUTRIN

See Contraindications. Avoid alcohol. Levodopa, amantadine may increase toxicity. Caution with drugs that lower seizure threshold (eg, quinolones, theophylline, antidiabetics, anorectics, CNS stimulants, systemic steroids, antidepressants, antipsychotics) or factors that lower seizure threshold (eg, opiate or cocaine addiction, excessive use of alcohol or sedatives). Caution with drugs metabolized by CYP2B6 (eg, orphenadrine, cyclophosphamide) or CYP2D6 including tricyclic antidepressants, SSRIs (eg, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), β-blockers (eg, metoprolol), Class 1C antiarrhythmics (eg, propafenone, flecainide); consider dose reduction. May be affected by metabolic enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin), or inhibitors (eg, cimetidine). Monitor for hypertension with nicotine replacement.

Adverse Reactions for WELLBUTRIN

CNS stimulation (eg, agitation, insomnia, seizures, tremor, dizziness), mania/hypomania, psychosis, weight change, dry mouth, headache, migraine, GI effects, edema, rash (rarely may be serious, eg, erythema multiforme, Stevens-Johnson syndrome), palpitations, urinary frequency, sweating, tinnitus, myalgia, hypertension.

How is WELLBUTRIN supplied?

XL tabs—30, 90
SR tabs—60
Immediate-rel tabs—100

Related Disease:

Depression

Related Resources

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions